Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 280 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prophylaxis D Clear all
Completed Phase 2Phase 3 Interventional Results available

Vitamin D/Calcium Polyp Prevention Study

NCT00153816
View directory record Official record
Conditions
Colorectal Cancer, Polyps, Adenomas
Interventions
Calcium Carbonate, Vitamin D3, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
2,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients

NCT05653232
View directory record Official record
Conditions
HCV
Interventions
Prophylaxis (P2W), Transmit and Treat (T&T)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

NCT03032406
View directory record Official record
Conditions
Breast Cancer Stage IIB
Interventions
Hydroxychloroquine, Everolimus
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

NCT01122381
View directory record Official record
Conditions
Headache, Migraine
Interventions
ethosuximide, placebo comparator
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

NCT03994731
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

NCT06323928
View directory record Official record
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT04232085
View directory record Official record
Conditions
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
Interventions
Alemtuzumab, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Months to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04329221
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer, Organ Transplant Recipients, Immunotherapy
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Prevention of Osteoporosis in Breast Cancer Survivors

NCT00567606
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

NCT02917096
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Ruxolitinib, Ruxolitinib Phosphate, Sirolimus, Tacrolimus
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00027560
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)

NCT04504981
View directory record Official record
Conditions
HIV, Drug Use
Interventions
Y2Prevent
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

HIV Pre-Exposure Prophylaxis Among an Unrecognized Sexual Minority Population

NCT05815030
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
video informational/educational intervention
Other
Lead sponsor
The Alternative Sexualities Health Research Alliance
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rio Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 25, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

RECLEAN Pilot Study

NCT04498845
View directory record Official record
Conditions
Lead Poisoning
Interventions
In-home assessment plan, Family educational session, Worker take home prevention training, D-LEAD cleaner products
Other · Behavioral
Lead sponsor
Boston University
Other
Eligibility
1 Year and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention

NCT03368456
View directory record Official record
Conditions
HIV/AIDS and Infections, Drug Abuse, Adolescent Behavior, Drug Usage
Interventions
S4E, Usual Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

NCT02074631
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Pamidronate, Calcium and vitamin D
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 20 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional

The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study

NCT00605631
View directory record Official record
Conditions
Post Myocardial Infarction
Interventions
Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Osteoporosis Prevention After Heart Transplant

NCT00000412
View directory record Official record
Conditions
Osteoporosis, Cardiac Transplantation
Interventions
Alendronate, Calcitriol, Placebo Alendronate, Placebo Calcitriol
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 70 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination

NCT03501992
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
Current care, Reminder-recall, Audit-and-feedback, Combined reminder-recall and audit-and-feedback
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years to 12 Years
Enrollment
9,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient-Directed Lifestyle Change and Health Promotion Program or Usual Care in Low-Income, Uninsured Participants in Los Angeles County, California

NCT00521209
View directory record Official record
Conditions
Impoverished Population
Interventions
Self-Care Stimulating Disease Prevention Program (SCSDPP), Stand procedures, no intervention
Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 25, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT06001385
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Interventions
Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide
Drug · Procedure · Other + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

NCT01246206
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 25, 2026, 10:14 PM EDT